Pharmaceutical

Opzelura by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval

Opzelura is under clinical development by Incyte and currently in Phase II for Graft Versus Host Disease (GVHD).

May 17, 2024 - 04:00
Opzelura is under clinical development by Incyte and currently in Phase II for Graft Versus Host Disease (GVHD).
Read the original article

Tags:

Previous Article

Opzelura by Incyte for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lu...

Next Article

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus B Infections: Like...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS

STAT+: FDA advisory panel recommends conditional approv...

Mar 22, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024

FDA approves Alvotech-Teva’s SIMLANDI jab for multiple conditions

FDA approves Alvotech-Teva’s SIMLANDI jab for multiple ...

Feb 26, 2024